UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Regulating the physical and chemical properties of gefitinib and its positional isomer through salt formation

Journal of molecular structure, 2025-02, Vol.1322, p.140328, Article 140328

2025

Volltextzugriff (PDF)

Design, synthesis and evaluation of new methyl piperazine derivatives as anticancer agents

Future journal of pharmaceutical sciences, 2024-12, Vol.10 (1), p.88-11, Article 88

2024

Volltextzugriff (PDF)

Shenqi Fuzheng injection restores the sensitivity to gefitinib in non-small cell lung cancer by inhibiting the IL-22/STAT3/AKT pathway

Pharmaceutical biology, 2024-12, Vol.62 (1), p.33-41

2024

Volltextzugriff (PDF)

Targeted nanoliposomes of oncogenic protein degraders: Significant inhibition of tumor in lung-cancer bearing mice

Journal of controlled release, 2024-12, Vol.376, p.502-517

2024

Volltextzugriff (PDF)

FTO promotes gefitinib-resistance by enhancing PELI3 expression and autophagy in non-small cell lung cancer

Pulmonary pharmacology & therapeutics, 2024-12, Vol.87, p.102317, Article 102317

2024

Volltextzugriff (PDF)

Harnessing the CD44-targeted delivery of self-assembled hyaluronan nanogel to reverse the antagonism between Cisplatin and Gefitinib in NSCLC cancer therapy

Carbohydrate polymers, 2024-11, Vol.344, p.122521, Article 122521

2024

Volltextzugriff (PDF)

Mechanistic insights into Yifei Sanjie pill's regulation of EMT to enhance gefitinib treatment effect in NSCLC by in silico analysis and experimental validation

Journal of ethnopharmacology, 2024-11, Vol.334, p.118343, Article 118343

2024

Volltextzugriff (PDF)

An innovative strategy for Gefitinib quantification in pharmaceutical and plasma samples using a graphene quantum dots-combined gold nanoparticles composite electrochemical sensor

Mikrochimica acta (1966), 2024-11, Vol.191 (11), p.697, Article 697

2024

Volltextzugriff (PDF)

Comparison of efficacy of gefitinib and osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer in patients with poor performance status

Respiratory investigation, 2024-11, Vol.62 (6), p.1137-1141

2024

Volltextzugriff (PDF)

Relevance and mechanism of STAT3/miR-221-3p/Fascin-1 axis in EGFR TKI resistance of triple-negative breast cancer

Molecular and cellular biochemistry, 2024-11, Vol.479 (11), p.3037-3047

2024

Volltextzugriff (PDF)

Cytochalasin H enhances sensitivity to gefitinib in non-small-cell lung cancer cells through inhibiting EGFR activation and PD-L1 expression

Scientific reports, 2024-10, Vol.14 (1), p.25276-13, Article 25276

2024

Volltextzugriff (PDF)

Bee venom prompts the inhibition of gefitinib on proliferation, migration, and invasion of non-small cell lung cancer cells via EGFR-mediated autophagy

Toxicon (Oxford), 2024-10, Vol.251, p.108149, Article 108149

2024

Volltextzugriff (PDF)

Antagonist of Growth Hormone-Releasing Hormone Receptor MIA-690 Suppresses the Growth of Androgen-Independent Prostate Cancers

International journal of molecular sciences, 2024-10, Vol.25 (20), p.11200

2024

Volltextzugriff (PDF)

FTO/m6A mediates miR-138-5p maturation and regulates gefitinib resistance of lung adenocarcinoma cells by miR-138-5p/LCN2 axis

BMC cancer, 2024-10, Vol.24 (1), p.1270-15, Article 1270

2024

Volltextzugriff (PDF)

Ubiquitin-specific protease 10 determines colorectal cancer outcome by modulating epidermal growth factor signaling via inositol polyphosphate-4-phosphatase type IIB

Oncogenesis (New York, NY), 2024-10, Vol.13 (1), p.37-12, Article 37

2024

Volltextzugriff (PDF)

Strategies for enhancing non-small cell lung cancer treatment: Integrating Chinese herbal medicines with epidermal growth factor receptor-tyrosine kinase inhibitors therapy

European journal of pharmacology, 2024-10, Vol.980, p.176871, Article 176871

2024

Volltextzugriff (PDF)

CRISPR-mediated ablation of TP53 and EGFR mutations enhances gefitinib sensitivity and anti-tumor efficacy in lung cancer

Molecular therapy, 2024-10, Vol.32 (10), p.3618-3628

2024

Volltextzugriff (PDF)

Inhibition of DDR1 promotes ferroptosis and overcomes gefitinib resistance in non-small cell lung cancer

Biochimica et biophysica acta. Molecular basis of disease, 2024-10, Vol.1870 (7), p.167447, Article 167447

2024

Volltextzugriff (PDF)

Efficacy on symptoms and mortality day vs. night administration of EGFR-TKIs for advanced non-small cell lung cancer

Supportive care in cancer, 2024-10, Vol.32 (10), p.645, Article 645

2024

Volltextzugriff (PDF)

EGFR inhibits TNF-α-mediated pathway by phosphorylating TNFR1 at tyrosine 360 and 401

Cell death and differentiation, 2024-10, Vol.31 (10), p.1318-1332

2024

Volltextzugriff (PDF)

HIF-1[alpha]-HPRT1 axis promotes tumorigenesis and gefitinib resistance by enhancing purine metabolism in EGFR-mutant lung adenocarcinoma

Journal of experimental & clinical cancer research, 2024-09, Vol.43 (1)

2024

Volltextzugriff (PDF)

HIF-1α-HPRT1 axis promotes tumorigenesis and gefitinib resistance by enhancing purine metabolism in EGFR-mutant lung adenocarcinoma

Journal of experimental & clinical cancer research, 2024-09, Vol.43 (1), p.269-14, Article 269

2024

Volltextzugriff (PDF)

An "AND" logic gate-based supramolecular therapeutic nanoplatform for combatting drug-resistant non-small cell lung cancer

Science advances, 2024-09, Vol.10 (39), p.eadp9071

2024

Volltextzugriff (PDF)

A Multi-Omics Prognostic Model Capturing Tumor Stemness and the Immune Microenvironment in Clear Cell Renal Cell Carcinoma

Biomedicines, 2024-09, Vol.12 (10), p.2171

2024

Volltextzugriff (PDF)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer: Current Use and Future Prospects

International journal of molecular sciences, 2024-09, Vol.25 (18), p.10008

2024

Volltextzugriff (PDF)

1 – 25 von 5.202

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(4.628)
Mit Volltextzugriff
(4.643)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

6 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Gefitinib
(4.764)
Science & Technology
(4.217)
Life Sciences & Biomedicine
(3.890)
Humans
(3.324)
Oncology
(2.404)
Lung Cancer
(1.774)
Lung Neoplasms - Drug Therapy
(1.749)
Mutation
(1.455)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(1.443)
Female
(1.406)
Male
(1.174)
Quinazolines - Therapeutic Use
(1.057)
Tumors
(1.036)
Antineoplastic Agents - Therapeutic Use
(1.027)
Lung Neoplasms - Genetics
(1.025)
Cell Line, Tumor
(1.013)
Epidermal Growth Factor
(997)
Middle Aged
(994)
Kinases
(970)
Aged
(940)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Lung Cancer
(200)
Plos One
(136)
Journal Of Thoracic Oncology
(108)
Anticancer Research
(79)
British Journal Of Cancer
(76)
Clinical Cancer Research
(74)
Clinical Lung Cancer
(68)
Scientific Reports
(68)
Annals Of Oncology
(66)
Cancer Chemotherapy And Pharmacology
(65)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Regulating the physical and chemical properties of gefitinib and its positional isomer through salt formation

Design, synthesis and evaluation of new methyl piperazine derivatives as anticancer agents

Shenqi Fuzheng injection restores the sensitivity to gefitinib in non-small cell lung cancer by inhibiting the IL-22/STAT3/AKT pathway

Targeted nanoliposomes of oncogenic protein degraders: Significant inhibition of tumor in lung-cancer bearing mice

FTO promotes gefitinib-resistance by enhancing PELI3 expression and autophagy in non-small cell lung cancer

Harnessing the CD44-targeted delivery of self-assembled hyaluronan nanogel to reverse the antagonism between Cisplatin and Gefitinib in NSCLC cancer therapy

Mechanistic insights into Yifei Sanjie pill's regulation of EMT to enhance gefitinib treatment effect in NSCLC by in silico analysis and experimental validation

An innovative strategy for Gefitinib quantification in pharmaceutical and plasma samples using a graphene quantum dots-combined gold nanoparticles composite electrochemical sensor

Comparison of efficacy of gefitinib and osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer in patients with poor performance status

Relevance and mechanism of STAT3/miR-221-3p/Fascin-1 axis in EGFR TKI resistance of triple-negative breast cancer

Cytochalasin H enhances sensitivity to gefitinib in non-small-cell lung cancer cells through inhibiting EGFR activation and PD-L1 expression

Bee venom prompts the inhibition of gefitinib on proliferation, migration, and invasion of non-small cell lung cancer cells via EGFR-mediated autophagy

Antagonist of Growth Hormone-Releasing Hormone Receptor MIA-690 Suppresses the Growth of Androgen-Independent Prostate Cancers

FTO/m6A mediates miR-138-5p maturation and regulates gefitinib resistance of lung adenocarcinoma cells by miR-138-5p/LCN2 axis

Ubiquitin-specific protease 10 determines colorectal cancer outcome by modulating epidermal growth factor signaling via inositol polyphosphate-4-phosphatase type IIB

Strategies for enhancing non-small cell lung cancer treatment: Integrating Chinese herbal medicines with epidermal growth factor receptor-tyrosine kinase inhibitors therapy

CRISPR-mediated ablation of TP53 and EGFR mutations enhances gefitinib sensitivity and anti-tumor efficacy in lung cancer

Inhibition of DDR1 promotes ferroptosis and overcomes gefitinib resistance in non-small cell lung cancer

Efficacy on symptoms and mortality day vs. night administration of EGFR-TKIs for advanced non-small cell lung cancer

EGFR inhibits TNF-α-mediated pathway by phosphorylating TNFR1 at tyrosine 360 and 401

HIF-1[alpha]-HPRT1 axis promotes tumorigenesis and gefitinib resistance by enhancing purine metabolism in EGFR-mutant lung adenocarcinoma

HIF-1α-HPRT1 axis promotes tumorigenesis and gefitinib resistance by enhancing purine metabolism in EGFR-mutant lung adenocarcinoma

An "AND" logic gate-based supramolecular therapeutic nanoplatform for combatting drug-resistant non-small cell lung cancer

A Multi-Omics Prognostic Model Capturing Tumor Stemness and the Immune Microenvironment in Clear Cell Renal Cell Carcinoma

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer: Current Use and Future Prospects

Suchergebnisse filtern